Cargando…
Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
INTRODUCTION: Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation. Anecdotally, cannabis use is frequently reported by consumers to promote sleep. However, there is limited research on the effects of cannabis on sleep and dayt...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239553/ https://www.ncbi.nlm.nih.gov/pubmed/32430450 http://dx.doi.org/10.1136/bmjopen-2019-034421 |
_version_ | 1783536713949249536 |
---|---|
author | Suraev, Anastasia Grunstein, Ronald R Marshall, Nathaniel S D'Rozario, Angela L Gordon, Christopher J Bartlett, Delwyn J Wong, Keith Yee, Brendon J Vandrey, Ryan Irwin, Chris Arnold, Jonathon C McGregor, Iain S Hoyos, Camilla M |
author_facet | Suraev, Anastasia Grunstein, Ronald R Marshall, Nathaniel S D'Rozario, Angela L Gordon, Christopher J Bartlett, Delwyn J Wong, Keith Yee, Brendon J Vandrey, Ryan Irwin, Chris Arnold, Jonathon C McGregor, Iain S Hoyos, Camilla M |
author_sort | Suraev, Anastasia |
collection | PubMed |
description | INTRODUCTION: Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation. Anecdotally, cannabis use is frequently reported by consumers to promote sleep. However, there is limited research on the effects of cannabis on sleep and daytime function in people with insomnia disorder using objective measures. This proof-of-concept study will evaluate the effects of a single dose of an oral cannabis-based medicine on sleep and daytime function in participants with chronic insomnia disorder. METHODS AND ANALYSIS: A randomised, crossover, placebo-controlled, single-dose study design will be used to test the safety and efficacy of an oral oil solution (‘ETC120’) containing 10 mg Δ(9)-tetrahydrocannabinol (THC) and 200 mg cannabidiol (CBD) in 20 participants diagnosed with chronic insomnia disorder. Participants aged 35–60 years will be recruited over an 18-month period commencing August 2019. Each participant will receive both the active drug and matched placebo, in a counterbalanced order, during two overnight study assessment visits, with at least a 1-week washout period between each visit. The primary outcomes are total sleep time and wake after sleep onset assessed via polysomnography. In addition, 256-channel high-density electroencephalography and source modelling using structural brain MRI will be used to comprehensively examine brain activation during sleep and wake periods on ETC120 versus placebo. Next-day cognitive function, alertness and simulated driving performance will also be investigated. ETHICS AND DISSEMINATION: Ethics approval was received from Bellberry Human Research Ethics Committee (2018-04-284). The findings will be disseminated in a peer-reviewed open-access journal and at academic conferences. TRIAL REGISTRATION NUMBER: ANZCTRN12619000714189. |
format | Online Article Text |
id | pubmed-7239553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-72395532020-05-28 Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial Suraev, Anastasia Grunstein, Ronald R Marshall, Nathaniel S D'Rozario, Angela L Gordon, Christopher J Bartlett, Delwyn J Wong, Keith Yee, Brendon J Vandrey, Ryan Irwin, Chris Arnold, Jonathon C McGregor, Iain S Hoyos, Camilla M BMJ Open Pharmacology and Therapeutics INTRODUCTION: Insomnia is a highly prevalent and costly condition that is associated with increased health risks and healthcare utilisation. Anecdotally, cannabis use is frequently reported by consumers to promote sleep. However, there is limited research on the effects of cannabis on sleep and daytime function in people with insomnia disorder using objective measures. This proof-of-concept study will evaluate the effects of a single dose of an oral cannabis-based medicine on sleep and daytime function in participants with chronic insomnia disorder. METHODS AND ANALYSIS: A randomised, crossover, placebo-controlled, single-dose study design will be used to test the safety and efficacy of an oral oil solution (‘ETC120’) containing 10 mg Δ(9)-tetrahydrocannabinol (THC) and 200 mg cannabidiol (CBD) in 20 participants diagnosed with chronic insomnia disorder. Participants aged 35–60 years will be recruited over an 18-month period commencing August 2019. Each participant will receive both the active drug and matched placebo, in a counterbalanced order, during two overnight study assessment visits, with at least a 1-week washout period between each visit. The primary outcomes are total sleep time and wake after sleep onset assessed via polysomnography. In addition, 256-channel high-density electroencephalography and source modelling using structural brain MRI will be used to comprehensively examine brain activation during sleep and wake periods on ETC120 versus placebo. Next-day cognitive function, alertness and simulated driving performance will also be investigated. ETHICS AND DISSEMINATION: Ethics approval was received from Bellberry Human Research Ethics Committee (2018-04-284). The findings will be disseminated in a peer-reviewed open-access journal and at academic conferences. TRIAL REGISTRATION NUMBER: ANZCTRN12619000714189. BMJ Publishing Group 2020-05-18 /pmc/articles/PMC7239553/ /pubmed/32430450 http://dx.doi.org/10.1136/bmjopen-2019-034421 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Pharmacology and Therapeutics Suraev, Anastasia Grunstein, Ronald R Marshall, Nathaniel S D'Rozario, Angela L Gordon, Christopher J Bartlett, Delwyn J Wong, Keith Yee, Brendon J Vandrey, Ryan Irwin, Chris Arnold, Jonathon C McGregor, Iain S Hoyos, Camilla M Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
title | Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
title_full | Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
title_fullStr | Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
title_full_unstemmed | Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
title_short | Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
title_sort | cannabidiol (cbd) and δ(9)-tetrahydrocannabinol (thc) for chronic insomnia disorder (‘cansleep’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239553/ https://www.ncbi.nlm.nih.gov/pubmed/32430450 http://dx.doi.org/10.1136/bmjopen-2019-034421 |
work_keys_str_mv | AT suraevanastasia cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT grunsteinronaldr cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT marshallnathaniels cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT drozarioangelal cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT gordonchristopherj cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT bartlettdelwynj cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT wongkeith cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT yeebrendonj cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT vandreyryan cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT irwinchris cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT arnoldjonathonc cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT mcgregoriains cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial AT hoyoscamillam cannabidiolcbdandd9tetrahydrocannabinolthcforchronicinsomniadisordercansleeptrialprotocolforarandomisedplacebocontrolleddoubleblindedproofofconcepttrial |